(Press-News.org) WHAT:
Two National Institutes of Health (NIH)-supported trials of an experimental malaria vaccine in healthy Malian adults found that all three tested regimens were safe. One of the trials enrolled 300 healthy women ages 18 to 38 years who anticipated becoming pregnant soon after immunization. That trial began with drug treatment to remove malaria parasites, followed by three injections spaced over a month of either saline placebo or the investigational vaccine at one of two dosages. Both dosages of the vaccine candidate conferred a significant degree of protection from parasite infection and clinical malaria that was sustained over a span of two years without the need for a booster dose—a first for any malaria vaccine. In an exploratory analysis of women who conceived during the study, the vaccine significantly protected them from malaria in pregnancy. If confirmed through additional clinical trials, the approach modeled in this study could open improved ways to prevent malaria in pregnancy.
Spread by Anopheles mosquitoes, malaria parasites, including those of the species Plasmodium falciparum (Pf), can cause illness in people of any age. However, pregnant women, infants and very young children are especially vulnerable to life-threatening disease. Malarial parasitemia in pregnancy is estimated to cause up to 50,000 maternal deaths and 200,000 stillbirths in Africa each year.
The trials were co-led by investigators from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and the University of Sciences, Techniques and Technologies, Bamako (USTTB), Mali. The investigational vaccine used in both trials was PfSPZ Vaccine, a radiation-attenuated vaccine based on Pf sporozoites (a stage of the parasite’s lifecycle), manufactured by Sanaria Inc., Rockville, Maryland. Multiple previous clinical trials of PfSPZ Vaccine have shown it to be safe, including in malaria-endemic countries such as Mali. In results published in 2022, for example, an NIAID-sponsored, placebo-controlled trial of a three-dose regimen of PfSPZ Vaccine in Burkina Faso found that the vaccine had up to 46% efficacy that lasted at least 18 months.
In the first year of the current trial, 55 women became pregnant within 24 weeks of the third vaccine dose. Among these women, vaccine efficacy against parasitemia (whether before or during pregnancy) was 65% in those who received the lower dose vaccine and 86% in those who received the higher dose. Among 155 women who became pregnant across both study years, vaccine efficacy was 57% for those who received lower dose vaccine and 49% in those in the higher dosage group.
Women who received the investigational vaccine at either of the dosages conceived sooner than those who received placebo, although this finding did not reach the level of statistical significance, reported the investigators. The researchers speculate that the PfSPZ Vaccine might avert malaria-related early pregnancy losses since parasitemia risk during the periconception period was reduced by 65 to 86%.
“Preconception immunization is a new strategy to reduce mortality for women with malaria in pregnancy,” the researchers note. They plan to investigate the safety of PfSPZ Vaccine administered during pregnancy, then examine the efficacy of PfSPZ given preconception or during pregnancy in larger clinical trials. “Existing measures are not protecting women from malaria in pregnancy,” they added. “A safe and effective vaccine is urgently needed, and our results indicate PfSPZ Vaccine might be a suitable candidate,” they conclude.
The PfSPZ Vaccine Study Team was led by Alassane Dicko, M.D., of the Malaria Research and Training Center (MRTC), USTTB, Mali, Stephen L. Hoffman, M.D., of Sanaria Inc., and Patrick E. Duffy, M.D., of the NIAID Laboratory of Malaria Immunology and Vaccinology. Joint co-first authors were Halimatou Diawara, M.D., of MRTC, and Sara A. Healy, M.D., NIAID.
Additional information about the trials is available at clinicaltrials.gov using the identifiers NCT03510481 or NCT03989102.
ARTICLE:
H Diawara et al. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases DOI: 10.1016/ S1473-3099(24)00360-8 (2024).
WHO:
Patrick E. Duffy, M.D., Chief, Laboratory of Malaria Immunology and Vaccinology, NIAID, is available to comment.
CONTACT:
To schedule interviews, please contact Anne A. Oplinger, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
Babies recognise pretence and around half of children can pretend themselves by 12 months, new research has found.
The study, led by the University of Bristol, shows for the first time how children’s awareness and grasp of pretence in its various forms develops from birth to three years.
Lead author Prof Elena Hoicka, Professor of Psychology in Education at the University’s School of Education, said: “Our findings highlight how pretending is a complex, evolving process which begins very early on in life, helping their cognitive and social skills to advance. Pretence ...
A new paper from the Smith School of Enterprise and the Environment, University of Oxford concludes that current climate standards are not sufficiently incentivising the big picture innovations necessary to deliver net zero, and must be expanded to include a company’s broader influence on climate action. The peer-reviewed research, published in Carbon Management, comes after a period of fierce public debate about climate standards and offers possible solutions for those seeking to improve both integrity and impact of corporate climate action.
Incentivising climate action and innovation in the corporate world is essential says co-author Dr Matilda Becker: “Of the 2000 largest ...
Anahita Khojandi and Xiaopeng Zhao have been selected by the American Association for the Advancement of Science (AAAS) to participate in the 2024-25 Science & Technology Policy Fellowship (STPF).
Khojandi, a Heath Endowed Faculty Fellow in Business & Engineering and Associate Professor in the Department of Industrial and Systems Engineering, and Zhao, a professor in the Department of Mechanical, Aerospace, and Biomedical Engineering and founding director of the Applied AI Program ...
New research from UC Santa Cruz is finally giving you the go-ahead to sing in the shower as loud as you want. Because, as it turns out, you probably sound pretty darn good.
Psychologists wanted to study “earworms,” the types of songs that get stuck in your head and play automatically on a loop. So they asked people to sing out any earworms they were experiencing and record them on their phones when prompted at random times throughout the day. When researchers analyzed the recordings, they found that a remarkable proportion of them perfectly matched the pitch of the original songs they were based upon.
More specifically, 44.7% of recordings had a pitch error of 0 semitones, ...
Providing cancer care for someone who also has a chronic illness, such as diabetes or high blood pressure, requires a systematic, co-management approach to produce better cancer and overall health outcomes, said UNC Lineberger Comprehensive Cancer Center’s Samuel Cykert, MD.
Cancer patients with a chronic illness often experience poorer outcomes. This is especially true for Black patients. Contributing to this disparity, studies show, is the increased likelihood that people with chronic illnesses may not be offered standard cancer treatments like surgery, chemotherapy or radiation. If they do start standard treatment, they might not complete it due to complications from ...
CHICAGO—August 14, 2024—Each year, the American Ornithological Society (AOS) confers awards on individuals and groups for their ornithological research and notable contributions to the science and practice of ornithology, and for their service to the society. Our 2024 awardees represent outstanding contributions to the scientific study and conservation of birds and to the AOS. The 2024 recipients will accept their awards at the AOS annual meeting (AOS 2024) in Estes Park, Colorado, in October.
“Our award winners this year epitomize the excellence in research, publications, service, and conservation in ornithology towards which we all strive in our profession,” ...
Researchers at Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG) today announced a significant paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia (T-ALL), an aggressive and high-risk form of cancer, to one frequently driven by genetic changes in non-coding portions of our DNA. The collaborative study, supported by the Gabriella Miller Kids First Pediatric Research Program (Kids First) and National Institutes of Health (NIH) Common Fund, was published ...
A WEHI study could help solve a long-standing mystery into why a key immune organ in our bodies shrinks and loses its function as we get older.
The thymus is an organ essential for good health due to its ability to produce special immune cells that are responsible for fighting infections and cancer.
In a world-first, researchers have uncovered new cells that drive this ageing process in the thymus – significant findings that could unlock a way to restore function in the thymus and prevent our immunity from waning as we age.
Watch and embed the video: https://youtu.be/2x1UGqNh77w
At a glance
The thymus is an organ essential for our immune defence ...
Key takeaways
Venting about your frustrations with one friend to another may feel good, but it doesn’t necessarily reduce anger.
Experiments showed that people who listened to a friend vent liked and supported that person more than those who were vented about — but only if the person venting didn’t derogate or seem aggressive toward the other friend.
Venting might be an effective tool of competition for listeners’ affections precisely because it is not readily recognized as a tool of competition.
Venting about your frustrations with one friend to another isn’t necessarily cathartic, but it can make the friend you’re talking to like and ...
CLEVELAND – University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial. He says in the two years since the foundational pre-clinical work was completed, the team has shown that it’s feasible to manufacture BAFF CAR T-cells for human subjects. The innovation is introducing genes into T-cells via the process of electroporation in the Wesley Center for Immunotherapy at UH Seidman Cancer Center.
In January 2022, a research team from UH Seidman Cancer Center and Case Western Reserve University published a groundbreaking ...
